Johnson & Johnson has sued four doctors who published studies citing links between talc-based personal care products and cancer, escalating an attack on scientific studies that the company alleges are inaccurate.
The secondary patent particularly irked some advocates because the drug’s development was largely underwritten by public funds, according to a 2020 analysis. That study found public sector funds contributed $455 million to $747 million to getting bedaquiline to market, compared to $90 million to $240 million from J&J.
We pay for the development of the drug, they get the patent, then we pay for the drug. Socialize cost, privatize profits.
We pay for the development of the drug, they get the patent, then we pay for the drug. Socialize cost, privatize profits.